NCT02328755View on ClinicalTrials.gov

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

peg-IFN-α

PROCEDURE

Hematopoietic Cell Transplant (HCT)

DRUG

Tacrolimus

Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.

DRUG

Methotrexate

Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02328755 - Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter